ALKERMES | ALKS - Net Income

Stock Price
33.31
Daily Change
-0.60 -1.77%
Monthly
13.42%
Yearly
19.65%
Q2 Forecast
32.32

ALKERMES reported $49.34M in Net Income for its fiscal quarter ending in December of 2025.





Net Income Change Date
AbbVie USD 1.82B 1.63B Dec/2025
Acadia Pharmaceuticals USD 273.57M 201.79M Dec/2025
ALKERMES USD 49.34M 33.42M Dec/2025
Amgen USD 1.33B 1.88B Dec/2025
Biogen USD 466.5M 168.3M Sep/2025
BioMarin Pharmaceutical USD -46.57M 15.83M Dec/2025
Bristol-Myers Squibb USD 1.09B 1.11B Dec/2025
Coherus Biosciences USD -37.64M 2.11M Dec/2025
Eli Lilly USD 6.64B 1.05B Dec/2025
Gilead Sciences USD 2.18B 869M Dec/2025
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Ionis Pharmaceuticals USD -229M 100.39M Dec/2025
J&J USD 5.24B 119M Mar/2026
Malin Corporation EUR -1.1M 2.2M Dec/2023
Merck USD 2.96B 2.82B Dec/2025
Minerva Neurosciences USD 1.44M 21.07M Dec/2024
Nektar Therapeutics USD -36.08M 978K Dec/2025
Neurocrine Biosciences USD 209.5M 102M Sep/2025
Otsuka Holdings JPY 65.49B 58.64B Dec/2025
Ovoca Bio EUR -765K 4.89M Jun/2025
Pfizer USD -1.65B 5.19B Dec/2025
Regeneron Pharmaceuticals USD 844.6M 615.4M Dec/2025
Vertex Pharmaceuticals USD 1.19B 108.2M Dec/2025